|
|
|
|
| LEADER |
01713nam a22003975i 4500 |
| 001 |
978-3-7643-7438-9 |
| 005 |
20191028142121.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2006 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764374389
|
| 024 |
7 |
|
|a 10.1007/3-7643-7438-1
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a TNF-alpha Inhibitors
|c edited by Jeffrey M. Weinberg, Robin Buchholz.
|
| 250 |
|
|
|a 1st ed. 2006.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2006.
|
| 300 |
|
|
|a X, 133 p. 10 illus.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a to TNF/pathophysiology of TNF -- History of development of TNF inhibitors -- Pharmacology of TNF inhibitors -- Etanercept in rheumatology -- Etanercept in dermatology and off-label use -- Infliximab in rheumatology -- Infliximab in dermatology, gastroenterology, and off-label use -- Adalimumab in rheumatology -- Adalimumab in dermatology -- A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Rheumatology.
|
| 650 |
|
0 |
|a Dermatology.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Gastroenterology .
|
| 650 |
1 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Rheumatology.
|
| 650 |
2 |
4 |
|a Dermatology.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Gastroenterology.
|
| 700 |
1 |
|
|a Weinberg, Jeffrey M.
|e editor.
|
| 700 |
1 |
|
|a Buchholz, Robin.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/3-7643-7438-1
|